No quarterly revenue total was found in WEREWOLF THERAPEUTICS, INC.'s SEC filings.
Werewolf Therapeutics, Inc. (HOWL) files with the SEC under industry code 2834, Pharmaceutical Preparations. As of Jun 30, 2026 it held $22.0 million in cash and investments and $0 in total debt.
Revenue
—
Net income
$3.67M
+120.4% vs year-ago quarter
Operating cash flow
$6.63M
+143.7% vs year-ago quarter
Free cash flow
$-11.02M
+23.3% vs year-ago quarter
EPS
$0.08
+120.0% vs year-ago quarter
Dividend per share
None
Shares outstanding
48.60M
+6.3% vs year-ago quarter
Net cash
$21.99M
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- HOWL (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Waltham, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1785530
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | $7.2M | -$13.3M | -$9.4M | -$15.7M | -$17.5M |
| Net income | $3.7M | -$13.5M | -$8.4M | -$16.4M | -$18.0M |
| Diluted EPS | $0.08 | -$0.28 | -$0.16 | -$0.36 | -$0.40 |
| Operating cash flow | $6.6M | -$10.6M | -$11.0M | -$15.2M | -$15.2M |
| Free cash flow | — | — | -$11.0M | -$15.2M | -$15.2M |
| Total assets | $24.2M | $58.0M | $69.4M | $79.6M | $92.6M |
| Total liabilities | $7.9M | $45.8M | $44.6M | $50.0M | $51.1M |
| Stockholders' equity | $16.3M | $12.2M | $24.8M | $29.6M | $41.5M |
| Cash and investments | $22.0M | $46.5M | $57.0M | $65.7M | $77.6M |
| Total debt | $0 | $40.9M | $41.5M | $41.7M | $42.1M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Aug 21, 2026 | Aug 21, 2026 |
| 8-K |
Current report
Material agreement
|
Aug 20, 2026 | Aug 14, 2026 |
| 10-Q | Quarterly report | Jul 31, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Jul 31, 2026 | Jul 31, 2026 |
| 10-Q | Quarterly report | May 7, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 7, 2026 | May 7, 2026 |
All 450 Werewolf Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.